IPO
Evelo Biosciences, Inc., a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, announced that it has entered into a loan and security agreement for up to $45 million with K2 HealthVentures, a healthcare investment firm.
Net sales increased 10 per cent compared to Q2 2018, corresponding to the net of acquisitions and discontinuing operations.
Delivered 31% increase in revenue, 51% increase in operating profit and 60% increase in net profit year-on-year Delivered 21% increase in revenue, with increases in operating profit and net profit compared to Q1 2019 Increased investment in pipeline to support long-term growth
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, provides a trading update for the six month period ended 30 June 2019.
Double-digit sales growth delivered by Pharma Biotech & Nutrition (LPBN) segment
Retrophin, Inc. announced it will report second quarter 2019 financial results on Tuesday, August 6, 2019 after the close of the U.S. financial markets.
The Fund has now invested a total of USD 30 million in six companies
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, announced that it will host a conference call on Thursday, August 1, 2019 at 5pm ET to discuss second quarter 2019 financial results and provide a corporate update.
Recipharm AB will publish its interim report for January - June 2019 on 25th July at 07:45 am CET.
Revenue and EBITDA for full year 2019 expected to be ahead of market expectations
PRESS RELEASES